Short interfering RNA for treating cancer

Disclosed herein is novel double-stranded short busybodied polymer (siRNA) capable of suppressing the interpretation of Aurora-A RNA. additionally disclosed are use of the novel siRNA as disclosed herein for producing a medicine appropriate for treating a cancer, that is mediate through epidermic protein receptor (EGFR) communication. consequently, a pharmaceutical composition comprising the disclosed novel siRNA molecules is provided; further as a technique of treating a theme stricken by EGFR-mediated cancer via administering to the topic the disclosed novel siRNA molecule. [1]

The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study


Colorectal cancer is related to completely different anatomical, biological, and clinical characteristics. we have a tendency to determined the impact of the first growth location in patients with pathologic process body part cancer (mCRC).


Demographic information and clinical info were collected from one,115 patients from the Republic of peninsula, World Health Organization conferred with mCRC between Gregorian calendar month 2009 and Gregorian calendar month 2011, mistreatment web-based electronic case report forms. Associations between the first growth location and therefore the patient’s clinical characteristics were assessed, and factors inf luencing overall survival were analyzed mistreatment Cox proportional hazards regression models.


Of the 1,115 patients recruited to the study, 244 (21.9%) had right carcinoma, 483 (43.3%) had left carcinoma, and 388 (34.8%) had body part cancer. Liver and respiratory organ metastases occurred additional ofttimes in patients with left colon and body part cancer (p = zero.005 and p = zero.006, respectively), whereas serous membrane and female internal reproductive organ metastases occurred additional ofttimes in patients with right and left carcinoma (p < zero.001 and p = zero.031, respectively). The median overall survival of patients with tumors originating within the right colon was considerably shorter than that of patients whose tumors had originated in the left colon or body part (13.7 months [95% confidence interval (CI), 12.0 to 15.5] vs. 18.0 months [95% CI, 16.3 to 19.7] or 19.9 months [95% CI, 18.5 to 21.3], respectively; p = zero.003). growth operation, the quantity of pathologic process sites, and first growth location related to with overall survival within the univariate and variable analyses.


Primary growth location influences the pathologic process sites and prognosis of patients with mCRC. [2]

Selenium Nanoparticles Induce the Chemo-Sensitivity of Fluorouracil Nanoparticles in Breast and Colon Cancer Cells

Drug resistance could be a major challenge of breast and carcinoma therapies resulting in treatment failure. the most objective of this study is to research whether or not chemical element nanoparticles (nano-Se) will induce the chemo-sensitivity of 5-fluorouracil (FU)-encapsulated poly (D, L-lactide-co-glycolide) nanoparticles (nano-FU) in breast and carcinoma cell lines. Nano-Se and nano-FU were synthesized and characterised, then applied one by one or together upon MCF7, MDA-MB-231, HCT 116, and Caco-2 cancerous cell lines. toxicity, cellular aldohexose uptake, and cell death, furthermore as malondialdehyde (MDA), gas (NO), and metallic element (Zn) levels, were investigated upon the various treatments. we’ve resulted that nano-FU iatrogenic necrobiosis in MCF7 and Caco-2 additional effectively than MDA-MB-231 and HCT 116 cell lines. Moreover, nano-FU and nano-Se raise MCF7 and Caco-2 chemo-sensitivity were beyond MDA-MB-231 and HCT 116 cancerous cell lines. it’s relevant to notice that Se and FU nano-formulations suppressed neoplastic cell bioenergetics via aldohexose uptake slight blockage. what is more, nano-FU enhanced the degree of NO and MDA in media over cancer cells, whereas their combos with nano-Se rebalance the oxidation-reduction standing with Zn increment. we tend to noticed  that MCF7 cell line is sensitive, whereas MDA-MB-231 cell line is immune to Se and nano-Se. This novel approach may well be of nice potential to reinforce the chemo-sensitivity in breast and carcinoma cells. [3]

SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer

DNA match repair macromolecule deficient carcinoma often displays reduced CDX2 expression, and up to date literature has recommended that negative CDX2 expression may be a poor prognostic biomarker in carcinoma. we’ve recently incontestible that SATB2 is AN immunohistochemical marker that’s complementary to CDX2. employing a tissue microarray approach, we have a tendency to evaluated SATB2 and CDX2 immunohistochemical expression in 514 patients with colonic carcinoma as well as 146 with match repair macromolecule deficient tumors and correlative expression with histopathologic variables, molecular alterations, and survival. Overall, SATB2-negative and/or CDX2-negative expression was known in thirty three of match repair macromolecule deficient tumors compared with solely fifteenth of mismatch repair protein practiced tumors (p. [4]

Colon Cancers: Epidemiological and Histopathological Aspects in Cameroon

Objective: to see the medicine and histologic profile of carcinoma in Cameroon.

Materials and Methods: it absolutely was a retrospective descriptive and analytical study on cancers of the colon, histologically established for thirteen years (2004-2016), listed within the registers laboratories of pathology and medicine of the national territory. The variables studied were the frequency, age, gender, risk factors, location and histopathologic kind.

Results: we tend to known 1047 cases of organic process cancers. The colon with 366 cases (26. 01%) was the second commonest location behind the abdomen. the common age of the patients was fifty two. 82 ± 15. 92 years, with extremes starting from six to eighty nine years previous. The male was the foremost pictured with fifty two. seventy three (193 cases), with a male-to-female sex quantitative relation of one.12. A tumor was sigmoid localisation in thirty seven. fifty nine of the cases (100 cases on 266 listed locations). Adenocarcinomas were the primary histologic kind with 311 cases (84. 97%) followed by the Kaposi cancer (21 cases; five.74 percent) and lymphomas (17 cases; four.65%).

Conclusion: Colon cancers stay a comparatively common pathology in Cameroon wherever it ranks second among malignant tumours of the alimentary tract. girls stay less affected than men by this pathology whose dominant histologic kind is glandular cancer. However, these information stay relative given the absence of a cancer register at the national level. [5]


[1] Hung, L.Y., Lai, C.H., Tseng, T.C., Jeng-Chang, L.E.E. and Lin, B.W., National Cheng Kung University, 2019. Short interfering RNA for treating cancer. U.S. Patent Application 10/174,322. (Web Link)

[2] Byun, J.H., Ahn, J.B., Kim, S.Y., Kang, J.H., Zang, D.Y., Kang, S.Y., Kang, M.J., Shim, B.Y., Baek, S.K., Kim, B.S. and Lee, K.H., 2019. The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study. The Korean journal of internal medicine, 34(1), p.165. (Web Link)

[3] Abd-Rabou, A.A., Shalby, A.B. and Ahmed, H.H., 2019. Selenium nanoparticles induce the chemo-sensitivity of fluorouracil nanoparticles in breast and colon cancer cells. Biological trace element research, 187(1), pp.80-91. (Web Link)

[4] SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer

Changqing Ma, Dane Olevian, Caitlyn Miller, Cameron Herbst, Priya Jayachandran, Margaret M. Kozak, Daniel T. Chang & Reetesh K. Pai

Modern Pathology (2019) (Web Link)

[5] Paul Ndamba Engbang, J., Fewou, A., Hasigov, A., Daniel Njel, O., Djimeli Djougmo, B., Gilbert Ateba, R., Godefroy, S., Moune, A., Adiogo, D. and Louis Oyono Essame, J. (2018) “Colon Cancers: Epidemiological and Histopathological Aspects in Cameroon”, Journal of Cancer and Tumor International, 7(1), pp. 1-13. doi: 10.9734/JCTI/2018/38860. (Web Link)


Related Post

Leave a Reply

Your email address will not be published. Required fields are marked *